WO2023235795A3 - Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders - Google Patents

Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders Download PDF

Info

Publication number
WO2023235795A3
WO2023235795A3 PCT/US2023/067754 US2023067754W WO2023235795A3 WO 2023235795 A3 WO2023235795 A3 WO 2023235795A3 US 2023067754 W US2023067754 W US 2023067754W WO 2023235795 A3 WO2023235795 A3 WO 2023235795A3
Authority
WO
WIPO (PCT)
Prior art keywords
granulocyte
disorders
stimulating factor
pulmonary
macrophage colony
Prior art date
Application number
PCT/US2023/067754
Other languages
French (fr)
Other versions
WO2023235795A2 (en
Inventor
Edwin ROCK
Ila JOSHI
Hillard LAZARUS
Original Assignee
Partner Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Partner Therapeutics, Inc. filed Critical Partner Therapeutics, Inc.
Publication of WO2023235795A2 publication Critical patent/WO2023235795A2/en
Publication of WO2023235795A3 publication Critical patent/WO2023235795A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

The present disclosure relates to the treatment of respiratory or pulmonary diseases or disorders with granulocyte-macrophage colony-stimulating factor.
PCT/US2023/067754 2022-06-01 2023-06-01 Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders WO2023235795A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263347781P 2022-06-01 2022-06-01
US63/347,781 2022-06-01

Publications (2)

Publication Number Publication Date
WO2023235795A2 WO2023235795A2 (en) 2023-12-07
WO2023235795A3 true WO2023235795A3 (en) 2024-02-08

Family

ID=89025650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/067754 WO2023235795A2 (en) 2022-06-01 2023-06-01 Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders

Country Status (1)

Country Link
WO (1) WO2023235795A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200323959A1 (en) * 2019-04-09 2020-10-15 Washington University Compositions for treating or preventing respiratory tract infections and method of use thereof
WO2021217020A1 (en) * 2020-04-23 2021-10-28 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based infection treatments
WO2023154855A2 (en) * 2022-02-11 2023-08-17 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200323959A1 (en) * 2019-04-09 2020-10-15 Washington University Compositions for treating or preventing respiratory tract infections and method of use thereof
WO2021217020A1 (en) * 2020-04-23 2021-10-28 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based infection treatments
WO2023154855A2 (en) * 2022-02-11 2023-08-17 Partner Therapeutics, Inc. Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI KUN, WOHLFORD-LENANE CHRISTINE, PERLMAN STANLEY, ZHAO JINCUN, JEWELL ALEXANDER K., REZNIKOV LEAH R., GIBSON-CORLEY KATHERINE N.: "Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4", JOURNAL OF INFECTIOUS DISEASES, UNIVERSITY OF CHICAGO PRESS, US, vol. 213, no. 5, 1 March 2016 (2016-03-01), US , pages 712 - 722, XP093138436, ISSN: 0022-1899, DOI: 10.1093/infdis/jiv499 *
MEYERHOLZ DAVID K, LAMBERTZ ALLYN M, MCCRAY PAUL B, PEDIATRICS, M D, PBDB 6320: "Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract Implications for the Middle East Respiratory Syndrome From the Departments of Pathology", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 186, no. 1, 1 January 2016 (2016-01-01), pages 79 - 86, XP055903519 *

Also Published As

Publication number Publication date
WO2023235795A2 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
WO2020092667A8 (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EA201790660A1 (en) KINAZ INHIBITOR
WO2020163823A3 (en) Therapeutic agents and methods of treatment
MX2021010888A (en) Heteroaromatic and heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders.
AU2019207704B2 (en) Growth factor otic formulations
MX2023009223A (en) Combination therapy for treating abnormal cell growth.
MX2022008103A (en) Amorphous kinase inhibitor formulations and methods of use thereof.
IL304306A (en) Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases
EP3914231A4 (en) Treatment of skin disorders with topical tapinarof combination compositions
WO2020063788A8 (en) Fgfr4 inhibitor and use thereof
AU2022259716B2 (en) Treatment of pain with polysulfated polysaccharides
WO2023081830A3 (en) Compositions and treatments with nirogacestat
MX2022009839A (en) Long-acting gm-csf and methods of use.
WO2023235795A3 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders
EP3927428A4 (en) Methods of treatment of respiratory disorders
WO2023154855A3 (en) Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders
IL304471A (en) Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases
MX2023004942A (en) Bicyclic compounds and uses thereof for the treatment of diseases.
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases
EP4069847A4 (en) Treatment of lower airways disorders
MX2022005490A (en) Methods of treating depressive disorders.
EP3955914A4 (en) Novel compounds and methods of use treating fructose-related disorders or diseases
WO2023215803A3 (en) Cytochrome bd oxidase inhibitors and uses thereof
EP3877382A4 (en) Novel compounds for the treatment of respiratory diseases
MX2023007218A (en) Cocrystal of a cdk inhibitor.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23816930

Country of ref document: EP

Kind code of ref document: A2